Oxcarbazepine

pharmacological · nervous · Oral

Oxcarbazepine. Carbamazepine analog — voltage-gated Na+ channel blocker. Active 10-MHD metabolite. Less CYP induction than carbamazepine + no… Oral half-life 9 h.

Carbamazepine analog — voltage-gated Na+ channel blocker. Active 10-MHD metabolite. Less CYP induction than carbamazepine + no auto-induction → cleaner DDI profile. Hyponatremia in 2.5% (more than carbamazepine).

PK: THIS RECORD IS A PARENT/METABOLITE CHIMERA and its own cited paper measured the METABOLITE, describing it as "the major component in plasma, the active monohydroxy metabolite (MHD), which is responsible for the therapeutic effect in man". The stored mass of 252.27 is the parent; the 9 h half-life is the metabolite value, the parent being 1-5 h against 7-20 h for the metabolite, and the metabolite mass is 254.28. F 0.95 came from an INEQUALITY BOUND, "the bioavailability of the oral formulation of oxcarbazepine is high (>95%)", and is replaced by a pinned 1 on the qualitative statement that absorption is complete. V 50 L matches NEITHER molecule nor either metabolite enantiomer — the parent is 131 L and the enantiomers 23.6 and 31.7 L. ka 1.5 is dropped rather than replaced because absorption is fitted with TRANSIT COMPARTMENTS. Both references are interaction studies reporting the OTHER drug kinetics. The mass-versus-analyte question is a schema decision and is logged rather than silently changed. Separately verified and NOT a defect: this record shares mass 252.27 with phenytoin because they are constitutional isomers, both C15H12N2O2.

Pharmacokinetics

Related compounds

Sources: PMID:17516704, PMID:28528287